Skip to main content
×
×
Home

Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study

  • Jacques Bradwejn (a1), Antti Ahokas (a2), Dan J. Stein (a3), Eliseo Salinas (a4), Gerard Emilien (a4) and Timothy Whitaker (a5)...
Abstract
Background

Venlafaxine extended-release (ER) has proven efficacy in the treatment of anxiety symptoms in major depression, generalised anxiety disorder and social anxiety disorder.

Aims

To evaluate the efficacy, safety and tolerability of venlafaxine ER in treating panic disorder.

Method

Adult out-patients (n=361) with panic disorder were randomly assigned to receive venlafaxine ER (75–225 mg/day) or placebo for up to 10 weeks in a double-blind study.

Results

Venlafaxine ER was not associated with a greater proportion of patients free from full-symptom panic attacks at the finalon-therapy evaluation, but was associated with lower mean panic attack frequency and a higher proportion free from limited-symptom panic attacks, higher response and remission rates, and improvements in anticipatory anxiety, fear and avoidance. Adverse events were comparable with those of the drug in depression and anxiety disorders.

Conclusions

Venlafaxine ER seems to be effective and well tolerated in the short-term treatment of panic disorder.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Venlafaxine extended-release capsules in panic disorder
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Venlafaxine extended-release capsules in panic disorder
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Venlafaxine extended-release capsules in panic disorder
      Available formats
      ×
Copyright
Corresponding author
Dr Jacques Bradwejn, University of Ottawa Institute of Mental Health Research, Royal Ottawa Hospital, 1145 Carling Avenue, Ottawa, Ontario, Canada KIZ 7K4. Tel: +1-613-7226521, extension 6546; fax: + 1-613-7982973; e-mail: jbradwej@rohcg.on.ca
Footnotes
Hide All

Declaration of interest

J. B. received funding for a clinical trial from Pfizer, and for consultation from Glaxo Smith Kline, Wyeth Research and Servier. D.J.S. received research grants and/or consultancy honoraria from Astra Zeneva, Eli-Lilly, Glaxo Smith Kline, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Solvay and Wyeth. E. S., G. E. and T. W. are employees of Wyeth.

Footnotes
References
Hide All
Allgulander, C., Mangano, R., Zhang, J., et al (2004) Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Human Psychopharrnacology, 19, 387396.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). Washington, DC: APA.
Ballenger, J. C., Davidson, J. R. T., Lecrubier, Y., et al (1998) Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. Journal of Clinical Psychiatry, 59 (suppl. 8), 4754.
Bandelow, B., Hajak, G., Holzrichter, S., et al (1995) Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problems. International Clinical Psychopharmacology, 10, 8393.
den Boer, J. A. (1998) Pharmcotherapy of panic disorder: differential efficacy from a clinical viewpoint. Journal of Clinical Psychiatry, 59 (suppl. 8), 3036.
Endicott, J., Nee, J., Harrison, W., et al (1993) Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacology Bulletin, 29, 321326.
Gelenberg, A. I., Lydiard, R. B., Rudolph, R. L., et al (2000) Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. Journal of the American Medical Association, 283, 30823088.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology (ADM 76-338), pp. 217222. Washington, DC: US Department of Health, Education, and Welfare.
Hamilton, M. J. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 5662.
Lara, N., Baker, G. B., Archer, S. L., et al (2003) Increased cholesterol levels during paroxetine administration in healthy men. Journal of Clinical Psychiatry, 64, 14551459.
Lipman, R. S. (1982) Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacology Bulletin, 18, 6977.
Muth, E. A., Haskins, J. T., Moyer, J. A., et al (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochemical Pharmacology, 35, 44934497.
Nicholas, L. M., Ford, A. L., Esposito, S. M., et al (2003) The effects of mirtazapine on plasma lipid profiles in healthy subjects. Journal of Clinical Psychiatry, 64, 883889.
Otto, M. W., Tuby, K. S., Gould, R. A., et al (2001) An effect size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. American Journal of Psychiatry, 158, 19891992.
Peter, H., Hand, I., Hohagen, F., et al (2002) Serum cholesterol level comparison: control subjects, anxiety disorder patients, and obsessive-compulsive disorder patients. Canadian Journal of Psychiatry, 47, 557561.
Pollack, M. H., Worthington, J. J., Otto, M. W., et al (1996) Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacology Bulletin, 32, 667670.
Pollack, M. H., Rapaport, M. H., Fayyad, R., et al (2002) Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder. Journal of Psychiatric Research, 36, 229236.
Shear, M. K., Clark, D. & Feske, U. (1998) The road to recovery in panic disorder: response, remission, and relapse. Journal of Clinical Psychiatry, 59 (suppl. 8), 48.
Sheehan, D. V. (1983) The Anxiety Disease. New York: Charles Scribners.
Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59 (suppl. 20), 2233.
Smith, D., Dempster, C., Glanville, J., et al (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. British Journal of Psychiatry, 180, 396404.
Yeragani, V. K., Tancer, M., Uhde, T. (2003) Heart rate and QT interval variability: abnormal alpha-2 adrenergic function in patients with panic disorder. Psychiatry Research, 121, 185196.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study

  • Jacques Bradwejn (a1), Antti Ahokas (a2), Dan J. Stein (a3), Eliseo Salinas (a4), Gerard Emilien (a4) and Timothy Whitaker (a5)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *